Anemia

Clues to Spontaneous Resolution of Anemia in Hemodialysis Found

Clues to Spontaneous Resolution of Anemia in Hemodialysis Found

By

Restoration of iron homeostasis and normal hepcidin levels appears to play a key role in freeing hemodialysis patients from having to receive erythropoiesis-stimulating agents.

Anemia Severity Linked to LVH Risk in Pediatric Dialysis

Anemia Severity Linked to LVH Risk in Pediatric Dialysis

By

Time-averaged hemoglobin levels, not hemoglobin cycling, is associated with an increased risk of left ventricular hypertrophy in pediatric dialysis patients, a study found.

Study: Long-Term Darbepoetin Use Safe, Effective in Non-Dialysis CKD

Study: Long-Term Darbepoetin Use Safe, Effective in Non-Dialysis CKD

By

Japanese post-marketing study identified no new safety concerns among patients with non-dialysis chronic kidney disease treated with darbepoetin alfa and followed up for 3 years.

Gastrointestinal Lesions Common in Patients With CKD Anemia

Gastrointestinal Lesions Common in Patients With CKD Anemia

By

In a Spanish study, endoscopic evaluation of patients with CKD and anemia revealed that 68.2% of patients had at least 1 gastrointestinal lesion.

Obese HD Patients Need Less Erythropoietin to Treat Anemia

Obese HD Patients Need Less Erythropoietin to Treat Anemia

By

New study "adds to the evidence of obesity-associated advantages," researchers conclude.

Intermittent IV Iron Infusion May Be Better for HD Patients

Intermittent IV Iron Infusion May Be Better for HD Patients

By

In a small study, intermittent vs continuous administration of IV iron resulted in less hemoglobin variability in hemodialysis patients with anemia.

ESA Biosimilar Effective for Anemia in Hemodialysis Patients

ESA Biosimilar Effective for Anemia in Hemodialysis Patients

By

Researchers found "no clinically meaningful differences" in efficacy and safety between the biosimilar epoetin alfa-epbx and epoetin alfa.

Pre-Dialysis Anemia Ups Mortality After Dialysis Start

Pre-Dialysis Anemia Ups Mortality After Dialysis Start

By

Patients with vs without anemia prior to starting hemodialysis (HD) were more likely to die despite achieving target hemoglobin levels at month 4 after HD initiation.

Reducing PTH Might Improve Anemia in Hemodialysis

Reducing PTH Might Improve Anemia in Hemodialysis

By

Anemia control may be one more reason to treat elevated parathyroid hormone levels.

FGF23 Predicts Development of CKD Anemia

FGF23 Predicts Development of CKD Anemia

By

Anemia is 66% and 84% more likely to develop among patients in the 3rd and 4th quartiles of serum fibroblast growth factor 23 level vs those in the 1st quartile.

FDA Approves 'Biosimilar' Drug to Treat Certain Types of Anemia

FDA Approves 'Biosimilar' Drug to Treat Certain Types of Anemia

Retacrit is biosimilar to the drugs Epogen and Procrit.

Change in Red Blood Cell Distribution Width Tied With Mortality in HD

Change in Red Blood Cell Distribution Width Tied With Mortality in HD

By

In a study, increases in red blood cell distribution width during the first year of dialysis was associated with greater risks for death.

Vadadustat Maintains Hemoglobin Levels in Hemodialysis Patients

Vadadustat Maintains Hemoglobin Levels in Hemodialysis Patients

By

Patients' mean hemoglobin levels stayed relatively stable after converting from an erythropoiesis-stimulating agent to the investigational drug.

No Reduction in Platelets Found With IV Iron Use in CKD

No Reduction in Platelets Found With IV Iron Use in CKD

By

New study shows that IV iron repletion with sodium ferric gluconate complex increased platelet count significantly at week 3 post-infusion and non-significantly at week 4.

FDA Updates Triferic Label With New Safety Warning

FDA Updates Triferic Label With New Safety Warning

By

Clinicians should advise women who could become pregnant to use effective contraception before and after taking the anemia drug.

Anticoagulation Therapy May Prevent CV Events, Worsen Anemia in CKD

Anticoagulation Therapy May Prevent CV Events, Worsen Anemia in CKD

By

In a study, use of anticoagulants was associated with 85% fewer atherosclerotic events.

Calcitriol Found Not to Improve Hepcidin Levels in CKD

Calcitriol Found Not to Improve Hepcidin Levels in CKD

By

In a trial, oral calcitriol of 0.5 mcg daily did not reduce hepcidin levels in patients with stage 3 to 4 CKD.

Higher-Dose IV Iron Appears Safe in Dialysis

Higher-Dose IV Iron Appears Safe in Dialysis

By

Dialysis patients receiving more or less than 200 mg per month of IV iron had similar risks of death, infection, cardiovascular disease, and hospitalization, meta-analysis shows.

FDA Broadens Feraheme Use for Iron Deficiency Anemia

FDA Broadens Feraheme Use for Iron Deficiency Anemia

The Food and Drug Administration broadened the existing labeling for Feraheme (ferumoxytol injection) beyond the current chronic kidney disease indication.

Most CKD Patients With Anemia Show Limited Response to Oral Iron

Most CKD Patients With Anemia Show Limited Response to Oral Iron

By

In a 52-week trial, more than half of nondialysis-dependent chronic kidney disease patients with anemia treated with oral iron had no rise in their hemoglobin levels.

Anemia in Dialysis Patients Linked With Hemorrhagic Stroke

Anemia in Dialysis Patients Linked With Hemorrhagic Stroke

By

Patients with hemoglobin values of 9.7 g/dL or below had more than double the risk for hemorrhagic stroke compared with patients with hemoglobin values of 11.2 g/dL or above.

CERA Effective for Pediatric Hemodialysis Patients With Anemia

CERA Effective for Pediatric Hemodialysis Patients With Anemia

By

The safety profile of CERA is similar for children as for adults.

Lower IV Iron Dosing in Anemic Dialysis Patients May Be More Effective

Lower IV Iron Dosing in Anemic Dialysis Patients May Be More Effective

By

To support ESA therapy, IV iron at doses below 300 mg/month may be most effective for the average hemodialysis patient, according to an observational study.

Ceruloplasmin a Possible Marker of CKD in Sickle Cell Anemia

Ceruloplasmin a Possible Marker of CKD in Sickle Cell Anemia

Urinary ceruloplamin has potential to be a chronic kidney disease biomarker for patients with sickle cell anemia.

Darbepoetin Alfa Safe for Pediatric CKD Patients With Anemia

Darbepoetin Alfa Safe for Pediatric CKD Patients With Anemia

By

Researchers tested once weekly and biweekly administration of darbepoetin alfa in children aged 1 to 18 years not previously treated with an erythropoiesis-stimulating agent.

Residual Renal Function Not Linked to ESA Requirements

Residual Renal Function Not Linked to ESA Requirements

By

Researchers find no significant difference in the median erythropoietin resistance index between patients with versus without residual renal function.

Case: Treating Iron Deficiency Anemia in a Heart Failure Patient

Case: Treating Iron Deficiency Anemia in a Heart Failure Patient

To shed light on the often-challenging management of this common condition, a case of a hypothetical patient was presented to a doctor who specializes in advanced heart failure and transplant cardiology.

High ESA and Iron Doses Up CVD, Death Risk in Hemodialysis Patients

High ESA and Iron Doses Up CVD, Death Risk in Hemodialysis Patients

By

High doses of iron are associated with a significantly higher risk of cardiovascular disease, regardless of the dose of erythropoiesis-stimulating agent.

Ferric Citrate Approved for Anemia in CKD Patients

Ferric Citrate Approved for Anemia in CKD Patients

By

Study results show that the phosphate binder was superior to placebo in raising hemoglobin levels in non-dialysis-dependent CKD patients with iron-deficiency anemia.

IV Iron, Erythropoietin Equally Effective for Anemia in HD Patients

IV Iron, Erythropoietin Equally Effective for Anemia in HD Patients

By

Intravenous iron and erythropoietin produced a similar hemoglobin response among hemodialysis patients with moderate anemia.

Sign Up for Free e-newsletters